How can we optimize the use of methotrexate to treat pediatric patients with inflammatory skin diseases?

References

• Cronstein BN, Aune TM. Methotrexate and its mechanisms of action in inflammatory arthritis. Nat Rev Rheumatol. 2020;16(3):145–54. doi: 10.1038/s41584-020-0373-9
   PubMed Web of Science ®Google Scholar
• Thomas S, Fisher KH, Snowden JA, et al. Methotrexate is a JAK/STAT pathway inhibitor. PLoS One. 2015;10(7):e0130078. doi: 10.1371/journal.pone.0130078
   PubMed Web of Science ®Google Scholar
• Siegfried EC, Arkin LM, Chiu YE, et al. Methotrexate for inflammatory skin disease in pediatric patients: consensus treatment guidelines. Pediatr Dermatol. 2023;40(5):789–808. doi: 10.1111/pde.15327
   PubMedGoogle Scholar
• Taieb Y, Baum S, Ben Amitai D, et al. The use of methotrexate for treating childhood atopic dermatitis: a multicenter retrospective study. J DermatolTreat. 2019;30(3):240–4. doi: 10.1080/09546634.2018.1508816
   Google Scholar
• Purvis D, Lee M, Agnew K, et al. Long-term effect of methotrexate for childhood atopic dermatitis. J Paediatr Child Health. 2019;55(12):1487–91. doi: 10.1111/jpc.14478
   PubMed Web of Science ®Google Scholar
• Elsgaard S, Danielsen AK, Thyssen JP, et al. Drug survival of systemic immunosuppressive treatments for atopic dermatitis in a long-term pediatric cohort. Int J Womens Dermatol. 2021;7(5):708–715. doi: 10.1016/j.ijwd.2021.07.005
   PubMedGoogle Scholar
• Wang Q, Chen L. Methotrexate therapy for adult and paediatric moderate-to-severe atopic dermatitis: a PRISMA-compliant meta-analysis of data from daily practice. Australas J Dermatol. 2023. doi: 10.1111/ajd.14183
   Web of Science ®Google Scholar
• Barak Levitt JA, Alemi S, Ollech A, et al. Treatment with methotrexate in infants and toddlers with atopic dermatitis: a retrospective multi-center study. J Clin Med. 2023;12(16):5409. doi: 10.3390/jcm12165409
   PubMed Web of Science ®Google Scholar
• van Geel MJ, Oostveen AM, Hoppenreijs EP, et al. Methotrexate in pediatric plaque-type psoriasis: long-term daily clinical practice results from the child-CAPTURE registry. J DermatolTreat. 2015;26(5):406–412. doi: 10.3109/09546634.2014.996515
   Google Scholar
• Bruins FM, Van Acht MR, Bronckers IMGJ, et al. Real-world methotrexate use in a prospective cohort of paediatric patients with plaque psoriasis: effectiveness, adverse events and folic acid regimen. Acta Derm Venereol. 2022;102:adv00745. doi: 10.2340/actadv.v102.1000
   PubMed Web of Science ®Google Scholar
• Vena GA, Cassano N, Iannone F. Update on subcutaneous methotrexate for inflammatory arthritis and psoriasis. Ther Clin Risk Manag. 2018;14:105–16. doi: 10.2147/TCRM.S154745
   PubMed Web of Science ®Google Scholar
• Żuber Z, Turowska-Heydel D, Sobczyk M, et al. Methotrexate efficacy and tolerability after switching from oral to subcutaneous route of administration in juvenile idiopathic arthritis. Reumatologia. 2016;54(1):19–23. doi: 10.5114/reum.2016.58757
   PubMedGoogle Scholar
• Wang Z, Chen Y, Xiang X, et al. Systemic methotrexate treatment in 42 children with severe plaque psoriasis: a retrospective study in China. Dermatology. 2022;238(5):919–27. doi: 10.1159/000521262
   PubMed Web of Science ®Google Scholar
• Landis ET, Pichardo-Geisinger RO. Methotrexate for the treatment of pediatric alopecia areata. J DermatolTreat. 2018;29(2):145–8. doi: 10.1080/09546634.2017.1341608
   Google Scholar
• Kinoshita-Ise M, Sachdeva M, Martinez-Cabriales SA, et al. Oral methotrexate monotherapy for severe Alopecia Areata: a single center retrospective case series. J Cutan Med Surg. 2021;25(5):490–7. doi: 10.1177/1203475421995712
   PubMed Web of Science ®Google Scholar
• Albela H, Begum S, Wee AL, et al. Efficacy and tolerability of methotrexate in the treatment of severe paediatric alopecia areata. Skin Appendage Disord. 2022;8(3):206–10. doi: 10.1159/000521238
   PubMed Web of Science ®Google Scholar
• Royer M, Bodemer C, Vabres P, et al. Efficacy and tolerability of methotrexate in severe childhood alopecia areata. Br J Dermatol. 2011;165(2):407–10. doi: 10.1111/j.1365-2133.2011.10383.x
   PubMed Web of Science ®Google Scholar
• Phan K, Ramachandran V, Sebaratnam DF. Methotrexate for alopecia areata: a systematic review and meta-analysis. J Am Acad Dermatol. 2019;80(1):120–7.e2. doi: 10.1016/j.jaad.2018.06.064
   PubMed Web of Science ®Google Scholar
• Papara C, De Luca DA, Bieber K, et al. Morphea: the 2023 update. Front Med. 2023;10:1108623. doi: 10.3389/fmed.2023.1108623
   Web of Science ®Google Scholar
• Zulian F, Martini G, Vallongo C, et al. Methotrexate treatment in juvenile localized scleroderma: a randomized, double-blind, placebo-controlled trial. Arthritis Rheum. 2011;63(7):1998–2006. doi: 10.1002/art.30264
   PubMed Web of Science ®Google Scholar
• Koch SB, Cerci FB, Jorizzo JL, et al. Linear morphea: a case series with long-term follow-up of young, methotrexate-treated patients. J DermatolTreat. 2013;24(6):435–8. doi: 10.3109/09546634.2013.806769
   Google Scholar
• Bağlan E, Kızıldağ Z, Çağlayan Ş, et al. Remission rates and risk factors for relapse in pediatric morphea: a multicenter retrospective study of pediatric rheumatology academy (PeRA)-research group (RG). Clin Rheumatol. 2023;42(10):2855–60. doi: 10.1007/s10067-023-06677-7
   PubMed Web of Science ®Google Scholar
• Leong PY, Chiu TM, Wei JC, et al. Case report: successful treatment with methotrexate in a 10-year-old boy with co-occurrence of generalized psoriasis and vitiligo. Front Immunol. 2023;14:1255909. doi: 10.3389/fimmu.2023.1255909
   PubMed Web of Science ®Google Scholar
• Bronckers IMGJ, Seyger MMB, West DP, et al. Safety of systemic agents for the treatment of pediatric psoriasis. JAMA Dermatol. 2017;153(11):1147–57. doi: 10.1001/jamadermatol.2017.3029
   PubMed Web of Science ®Google Scholar
• Noubiap JJ, Nansseu JR, Lontchi-Yimagou E, et al. Global, regional, and country estimates of metabolic syndrome burden in children and adolescents in 2020: a systematic review and modelling analysis. Lancet Child Adolesc Health. 2022;6(3):158–70. doi: 10.1016/S2352-4642(21)00374-6
   PubMedGoogle Scholar
• Man S, Deng Y, Ma Y, et al. Prevalence of liver steatosis and fibrosis in the general population and various high-risk populations: a nationwide study with 5.7 million adults in China. Gastroenterology. 2023;165(4):1025–40. doi: 10.1053/j.gastro.2023.05.053
   PubMed Web of Science ®Google Scholar
• Solomon DH, Glynn RJ, Karlson EW, et al. Adverse effects of low-dose methotrexate: a randomized trial. Ann Intern Med. 2020;172(6):369–80. doi: 10.7326/M19-3369
   PubMed Web of Science ®Google Scholar
• Medyńska-Przęczek A, Stochel-Gaudyn A, Wędrychowicz A. Liver fibrosis assessment in pediatric population - can ultrasound elastography be an alternative method to liver biopsy? A systematic review. Adv Med Sci. 2024;69(1):8–20. doi: 10.1016/j.advms.2023.12.001
   PubMed Web of Science ®Google Scholar
• Niyasom C, Soponkanaporn S, Vilaiyuk S, et al. Use of transient elastography to assess hepatic steatosis and fibrosis in patients with juvenile idiopathic arthritis during methotrexate treatment. Clin Rheumatol. 2024;43(1):423–33. doi: 10.1007/s10067-023-06835-x
   PubMed Web of Science ®Google Scholar
• Gisondi P, Bellinato F, Bruni M, et al. Methotrexate vs secukinumab safety in psoriasis patients with metabolic syndrome. Dermatol Ther. 2020;33(6):e14281. doi: 10.1111/dth.14281
   PubMed Web of Science ®Google Scholar
• Krasowska D, Gambichler T, Cortés C, et al. Long-term efficacy, safety and tolerability of secukinumab in children and adolescents with severe chronic plaque psoriasis: two-year results from a phase III double-blind, randomized controlled trial. J Eur Acad Dermatol Venereol. 2023;37(8):1616–1625. doi: 10.1111/jdv.19063
   Web of Science ®Google Scholar
• Thaçi D, Papp K, Marcoux D, et al. Sustained long-term efficacy and safety of adalimumab in paediatric patients with severe chronic plaque psoriasis from a randomized, double-blind, phase III study. Br J Dermatol. 2019;181(6):1177–89. doi: 10.1111/bjd.18029
   PubMed Web of Science ®Google Scholar
• Rahman SI, Siegfried E, Flanagan KH, et al. The methotrexate polyglutamate assay supports the efficacy of methotrexate for severe inflammatory skin disease in children. J Am Acad Dermatol. 2014;70(2):252–6. doi: 10.1016/j.jaad.2013.10.001
   PubMed Web of Science ®Google Scholar
• Hawwa AF, AlBawab A, Rooney M, et al. Methotrexate polyglutamates as a potential marker of adherence to long-term therapy in children with juvenile idiopathic arthritis and juvenile dermatomyositis: an observational, cross-sectional study. Arthritis Res Ther. 2015;17(1):295. doi: 10.1186/s13075-015-0814-z
   PubMedGoogle Scholar
• Halyabar O, Mehta J, Ringold S, et al. Treatment withdrawal following remission in juvenile idiopathic arthritis: a systematic review of the literature. Paediatr Drugs. 2019;21(6):469–92. doi: 10.1007/s40272-019-00362-6
   PubMed Web of Science ®Google Scholar
• Flohr C, Rosala-Hallas A, Jones AP, et al. Efficacy and safety of ciclosporin versus methotrexate in the treatment of severe atopic dermatitis in children and young people (TREAT): a multicentre parallel group assessor-blinded clinical trial. Br J Dermatol. 2023;189(6):674–84. doi: 10.1093/bjd/ljad281
   PubMed Web of Science ®Google Scholar
• Koyama A, Tanaka A, To H. Daily oral administration of low-dose methotrexate has greater antirheumatic effects in collagen-induced arthritis rats. J Pharm Pharmacol. 2017;69(9):1145–54. doi: 10.1111/jphp.12752
   PubMed Web of Science ®Google Scholar
• Radmanesh M, Rafiei B, Moosavi ZB, et al. Weekly vs. daily administration of oral methotrexate (MTX) for generalized plaque psoriasis: a randomized controlled clinical trial. Int J Dermatol. 2011;50(10):1291–3. doi: 10.1111/j.1365-4632.2011.04967.x
   PubMed Web of Science ®Google Scholar
• Pinkerton CR, Welshman SG, Kelly JG, et al. Pharmacokinetics of low-dose methotrexate in children receiving maintenance therapy for acute lymphoblastic leukaemia. Cancer Chemother Pharmacol. 1982;10(1):36–9. doi: 10.1007/BF00257235
   PubMed Web of Science ®Google Scholar
• Chládek J, Grim J, Martínková J, et al. Pharmacokinetics and pharmacodynamics of low-dose methotrexate in the treatment of psoriasis. Br J Clin Pharmacol. 2002;54(2):147–56. doi: 10.1046/j.1365-2125.2002.01621.x
   PubMed Web of Science ®Google Scholar
• Fernandez E, Perez R, Hernandez A, et al. Factors and mechanisms for pharmacokinetic differences between pediatric population and adults. Pharmaceutics. 2011;3(1):53–72. doi: 10.3390/pharmaceutics3010053
   PubMedGoogle Scholar
• Dupuis LL, Koren G, Silverman ED, et al. Influence of food on the bioavailability of oral methotrexate in children. J Rheumatol. 1995;22(8):1570–3.
   PubMed Web of Science ®Google Scholar
• Pinkerton CR, Welshman SG, Glasgow JF, et al. Can food influence the absorption of methotrexate in children with acute lymphoblastic leukaemia? Lancet. 1980;2(8201):944–946. doi: 10.1016/S0140-6736(80)92105-4
   PubMed Web of Science ®Google Scholar
• Ariane M, Mahé E. Combined acitretin-methotrexate therapy seems safe and efficient in children with psoriasis. Annales de Dermatologie et de Vénéréologie. 2022;149(3):189–190. doi: 10.1016/j.annder.2022.02.004
   PubMed Web of Science ®Google Scholar
• Bronckers IMGJ, Paller AS, West DP, et al. A comparison of psoriasis severity in pediatric patients treated with methotrexate vs biologic agents. JAMA Dermatol. 2020;156(4):384–92. doi: 10.1001/jamadermatol.2019.4835
   PubMed Web of Science ®Google Scholar
• Papp K, Thaçi D, Marcoux D, et al. Efficacy and safety of adalimumab every other week versus methotrexate once weekly in children and adolescents with severe chronic plaque psoriasis: a randomised, double-blind, phase 3 trial. Lancet. 2017;390(10089):40–9. doi: 10.1016/S0140-6736(17)31189-3
   PubMed Web of Science ®Google Scholar
• Klufas DM, Wald JM, Strober BE. Treatment of moderate to severe pediatric psoriasis: a retrospective case series. Pediatr Dermatol. 2016;33(2):142–9. doi: 10.1111/pde.12782
   PubMed Web of Science ®Google Scholar
• Skrabl-Baumgartner A, Weger W, Salmhofer W, et al. Childhood generalized pustular psoriasis: longtime remission with combined infliximab and methotrexate treatment. Pediatr Dermatol. 2015;32(1):e13–4. doi: 10.1111/pde.12457
   PubMed Web of Science ®Google Scholar
• Mahé E, Beauchet A, Hadj-Rabia S, et al. Biologics combined with conventional systemic agents for the treatment of children with severe psoriasis. Real-life data from the BiPe cohorts and a practice survey among French and Italian pediatric dermatologists. Dermatol Ther. 2022;35(11):e15828. doi: 10.1111/dth.15828
   PubMed Web of Science ®Google Scholar
• Ducourau E, Rispens T, Samain M, et al. Methotrexate effect on immunogenicity and long-term maintenance of adalimumab in axial spondyloarthritis: a multicentric randomised trial. RMD Open. 2020;6(1):e001047. doi: 10.1136/rmdopen-2019-001047
   PubMed Web of Science ®Google Scholar
• van der Kraaij G, Busard C, van den Reek J, et al. Adalimumab with methotrexate vs. Adalimumab monotherapy in psoriasis: first-year results of a single-blind randomized controlled trial. J Invest Dermatol. 2022;142(9):2375–83.e6. doi: 10.1016/j.jid.2022.01.033
   PubMed Web of Science ®Google Scholar
• Krieckaert CL, Nurmohamed MT, Wolbink GJ. Methotrexate reduces immunogenicity in adalimumab treated rheumatoid arthritis patients in a dose dependent manner. Ann Rheum Dis. 2012;71(11):1914–5. doi: 10.1136/annrheumdis-2012-201544
   PubMed Web of Science ®Google Scholar
• Doeleman MJH, van Maarseveen EM, Swart JF. Immunogenicity of biologic agents in juvenile idiopathic arthritis: a systematic review and meta-analysis. Rheumatology (Oxford). 2019;58(10):1839–49. doi: 10.1093/rheumatology/kez030
   PubMed Web of Science ®Google Scholar
• Goss SL, Klein CE, Jin Z, et al. Methotrexate dose in patients with early rheumatoid arthritis impacts methotrexate polyglutamate pharmacokinetics, adalimumab pharmacokinetics, and efficacy: pharmacokinetic and exposure-response analysis of the CONCERTO trial. Clin Ther. 2018;40(2):309–19. doi: 10.1016/j.clinthera.2018.01.002
   PubMed Web of Science ®Google Scholar
• Szostak B, Machaj F, Rosik J, et al. Using pharmacogenetics to predict methotrexate response in rheumatoid arthritis patients. Expert Opin Drug Metab Toxicol. 2020;16(7):617–26. doi: 10.1080/17425255.2020.1777279
   PubMed Web of Science ®Google Scholar
• Cavalli M, Eriksson N, Sundbaum JK, et al. Genome-wide association study of liver enzyme elevation in an extended cohort of rheumatoid arthritis patients starting low-dose methotrexate. Pharmacogenomics. 2022;23(15):813–20. doi: 10.2217/pgs-2022-0074
   PubMed Web of Science ®Google Scholar
• Grželj J, Marovt M, Marko PB, et al. Polymorphism in gene for ABCC2 transporter predicts methotrexate drug survival in patients with psoriasis. Medicina (Kaunas). 2021;57(10):1050. doi: 10.3390/medicina57101050
   PubMed Web of Science ®Google Scholar
• Fan Z, Zhang Z, Huang Q, et al. The impact of ANxA6 gene polymorphism on the efficacy of methotrexate treatment in psoriasis patients. Dermatology. 2021;237(4):579–87. doi: 10.1159/000514072
   PubMed Web of Science ®Google Scholar
• Grželj J, Mlinarič-Raščan I, Marko PB, et al. Polymorphisms in GNMT and DNMT3b are associated with methotrexate treatment outcome in plaque psoriasis. Biomed Pharmacother. 2021;138:111456. doi: 10.1016/j.biopha.2021.111456
   PubMed Web of Science ®Google Scholar
• Wang B, Wang Z, Yang W, et al. Unlocking the role of the B7-H4 polymorphism in psoriasis: insights into methotrexate treatment outcomes: a prospective cohort study. Immunology. 2024;171(1):104–16. doi: 10.1111/imm.13704
   PubMed Web of Science ®Google Scholar
• Campagne O, Huang J, Lin T, et al. Population pharmacokinetics of methotrexate and 7-hydroxymethotrexate and delayed excretion in infants and young children with brain tumors. Eur J Pharm Sci. 2024;193:106669. doi: 10.1016/j.ejps.2023.106669
   PubMed Web of Science ®Google Scholar
• Rose CD, Singsen BH, Eichenfield AH, et al. Safety and efficacy of methotrexate therapy for juvenile rheumatoid arthritis. J Pediatr. 1990;117(4):653–9. doi: 10.1016/S0022-3476(05)80709-7
   PubMed Web of Science ®Google Scholar